These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38772169)

  • 41. Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer.
    Huppert LA; Gumusay O; Idossa D; Rugo HS
    CA Cancer J Clin; 2023; 73(5):480-515. PubMed ID: 36939293
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.
    Vaz-Luis I; Ottesen RA; Hughes ME; Marcom PK; Moy B; Rugo HS; Theriault RL; Wilson J; Niland JC; Weeks JC; Lin NU
    Breast Cancer Res; 2012 Oct; 14(5):R129. PubMed ID: 23025714
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
    Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
    BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical implications of the intrinsic molecular subtypes of breast cancer.
    Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
    Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape.
    Redfern A; Burslem K; Woodward N; Beith J; McCarthy N; De Boer R; Bell R
    Asia Pac J Clin Oncol; 2016 Mar; 12 Suppl 1():19-31. PubMed ID: 27001209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The clinical benefit of epidermal growth factor receptor and human epidermal growth factor receptor 2 targeted agents adding to endocrine therapy in hormone receptor-positive breast cancer.
    Li H; Zhai Q; Yu B
    J Cancer Res Ther; 2018; 14(Supplement):S218-S223. PubMed ID: 29578177
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
    Whitworth P; Beitsch P; Mislowsky A; Pellicane JV; Nash C; Murray M; Lee LA; Dul CL; Rotkis M; Baron P; Stork-Sloots L; de Snoo FA; Beatty J
    Ann Surg Oncol; 2017 Mar; 24(3):669-675. PubMed ID: 27770345
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
    AlFakeeh A; Brezden-Masley C
    Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.
    Su Y; Zheng Y; Zheng W; Gu K; Chen Z; Li G; Cai Q; Lu W; Shu XO
    BMC Cancer; 2011 Jul; 11():292. PubMed ID: 21749714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar.
    Agostinetto E; Curigliano G; Piccart M
    Cell Rep Med; 2024 Jun; 5(6):101575. PubMed ID: 38759648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer.
    Ju J; Du F; Gao SL; Si YR; Hu NL; Liu DX; Wang X; Yue J; Zheng FC; Kang YK; Yang ZX; Ma F; Xu BH; Yuan P
    Breast Cancer Res Treat; 2022 Jul; 194(2):221-230. PubMed ID: 35699854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Breast cancer recurrence according to molecular subtype.
    Shim HJ; Kim SH; Kang BJ; Choi BG; Kim HS; Cha ES; Song BJ
    Asian Pac J Cancer Prev; 2014; 15(14):5539-44. PubMed ID: 25081661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecularly targeted therapies for metastatic triple-negative breast cancer.
    Bayraktar S; Glück S
    Breast Cancer Res Treat; 2013 Feb; 138(1):21-35. PubMed ID: 23358903
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
    Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
    Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.
    Miranda F; Prazeres H; Mendes F; Martins D; Schmitt F
    Mol Biol Rep; 2022 Jan; 49(1):717-733. PubMed ID: 34739691
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular breast cancer subtypes and therapies in a public hospital of northeastern Brazil.
    de Macêdo Andrade AC; Ferreira Júnior CA; Dantas Guimarães B; Pessoa Barros AW; Sarmento de Almeida G; Weller M
    BMC Womens Health; 2014 Sep; 14():110. PubMed ID: 25216732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
    Blackwell K; Burris H; Gomez P; Lynn Henry N; Isakoff S; Campana F; Gao L; Jiang J; Macé S; Tolaney SM
    Breast Cancer Res Treat; 2015 Nov; 154(2):287-97. PubMed ID: 26497877
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Soliman H; Wagner S; Flake DD; Robson M; Schwartzberg L; Sharma P; Magliocco A; Kronenwett R; Lancaster JM; Lanchbury JS; Gutin A; Gradishar W
    Ann Surg Oncol; 2020 Mar; 27(3):765-771. PubMed ID: 31907749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.